HRTX Stock Analysis: Buy, Sell, or Hold?
HRTX - Heron Therapeutics, Inc.
$0.32
0.01 (2.98%)
▲
5d:
-5.49%
30d:
-30.68%
90d:
-63.48%
HOLD
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Get Alerted When HRTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: HRTX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: HRTX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: HRTX is currently trading at $0.32, which is considered oversold relative to its 30-day fair value range of $0.35 to $0.50. From a valuation perspective, the stock is trading at a discount (Forward PE: -2.9) compared to its historical average (1.9). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, HRTX is in a strong downtrend. Immediate support is located at $0.30, while resistance sits at $0.42.
Market Sentiment: HRTX scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $7.00 (+2099.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, HRTX is in a strong downtrend. Immediate support is located at $0.30, while resistance sits at $0.42.
Market Sentiment: HRTX scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $7.00 (+2099.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.35 -
$0.50
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
95.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 2099.9% below Wall St target ($7.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Bottoming setup, but lagging the sector by 30% over 20 days — wait for relative strength
- CAUTION: 5-day price weakness (-5.5%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$0.35 -
$0.50
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.30
Resistance Level
$0.42
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.89
Wall Street Target
$7.00
(+2099.9%)
Revenue Growth (YoY)
1.3%
Profit Margin
-22.5%
PE vs Historical
-2.9 vs 1.9
CHEAP
Share & Embed Analysis
Last updated: August 23, 2026 10:11 PM ET
Data refreshes hourly during market hours. Next update: 11:11 PM
Data refreshes hourly during market hours. Next update: 11:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HRTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 57 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
